LifeMD® to Report Third Quarter 2024 Financial Results on November 7
NEW YORK, Oct. 24, 2024 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care services,...
News
Tonix Pharmaceuticals Announces Oral Presentation at the World Vaccine Congress Europe 2024
CHATHAM, N.J., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage...
Vaxart to Showcase its COVID-19 and Norovirus Oral Pill Vaccine Candidates at World Vaccine Congress Europe 2024
SOUTH SAN FRANCISCO, Calif., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced that it will present...
Legend Biotech to Host Investor Conference Call on Third Quarter 2024 Results
SOMERSET, N.J., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell...
Senseonics Holdings, Inc. Schedules Third Quarter 2024 Earnings Release and Conference Call for November 7, 2024 at 4:30 P.M. Eastern Time
GERMANTOWN, Md., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on...
BioCryst Presents New Real-World Evidence Showing High Adherence and Persistence Rates with ORLADEYO® (berotralstat)
Additional real-world studies show sustained HAE attack rate reduction after initiating ORLADEYO, regardless of C1-INH status, and patient preference for...
Aquestive Therapeutics Announces Positive Topline Results from Oral Allergy Syndrome (OAS) Challenge Study for Anaphylm™ (epinephrine) Sublingual Film
Completed OAS challenge study meets both primary and secondary endpointsDemonstrates rapid resolution of allergen-related symptoms beginning two minutes after administration...
Arcutis Presents Positive Patient-Reported Outcome Data for ZORYVE® (Roflumilast) Cream 0.15% in Atopic Dermatitis at American College of Allergy, Asthma and Immunology 2024 Annual Scientific Meeting
New patient-reported outcome data from INTEGUMENT-1 and -2 demonstrate that ZORYVE cream 0.15% rapidly decreased the impact of atopic dermatitis...
Bionano Announces Publication Outlining Utility of OGM for Resolution of MYC Gene Rearrangements in Multiple Myeloma
Publication shows that OGM can resolve translocation partners involving MYC in multiple myeloma (MM) more effectively than current methodsThe release...
PeopleOne Health Secures up to $32.3 Million Series B Funding Led by GV (Google Ventures) to Expand Access to Affordable, High-Quality Primary Care
New funding will support strategic expansion of PeopleOne Health, improving access to preventive care and treatment to keep people healthier...
Kura Oncology Reports Preclinical Data Supporting Opportunity for Ziftomenib in Treatment of Gastrointestinal Stromal Tumors (GIST)
– Combination of ziftomenib and imatinib shows robust and durable antitumor activity in imatinib-sensitive (1L) and imatinib-resistant (2L/3L) GIST models...
Soligenix, Inc. to Present at the 2024 ThinkEquity Conference
PRINCETON, N.J., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Soligenix, Inc. (Nasdaq: SNGX) (“Soligenix” or the “Company”) a late-stage biopharmaceutical company...
BridgeBio Shares Positive Data from High Dose Cohort of Phase 1/2 CANaspire Study of Gene Therapy BBP-812 for Canavan Disease at ESGCT 2024
- Continued, progressive improvement in motor function and achievement of motor milestones at 12-months post-treatment represents an important and statistically...
Biogen to Present New Data at the Clinical Trials on Alzheimer’s Disease (CTAD) 2024 Annual Conference
CAMBRIDGE, Mass., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) announced upcoming data presentations and programming at the...
Prelude Therapeutics Presents New Data from SMARCA Degrader Portfolio at the 36th EORTC-NCI-AACR Symposium
– Interim data from ongoing trial of PRT3789 showed additional clinical activity at higher doses in patients with non-small cell...
Phio Pharmaceuticals Announces Upcoming Presentation at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
New clinical data from Phio's on-going Phase 1b trial to be presentedMarlborough, Massachusetts--(Newsfile Corp. - October 24, 2024) - Phio...
Phio Pharmaceuticals Announces Upcoming Presentation at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
New clinical data from Phio's on-going Phase 1b trial to be presentedMarlborough, Massachusetts--(Newsfile Corp. - October 24, 2024) - Phio...
Ludwig Enterprises Files Provisional Patent for Revolutionary Cancer Screening Algorithm, Plans 2024 Launch as Revealia(TM)
SPARKS, NV / ACCESSWIRE / October 24, 2024 / Ludwig Enterprises, Inc, (OTC PINK:LUDG), a leading USA-based biotechnology company, has...
Ludwig Enterprises Files Provisional Patent for Revolutionary Cancer Screening Algorithm, Plans 2024 Launch as Revealia(TM)
SPARKS, NV / ACCESSWIRE / October 24, 2024 / Ludwig Enterprises, Inc, (OTC PINK:LUDG), a leading USA-based biotechnology company, has...
CASI Pharmaceuticals Receives CTA Approval From China’s NMPA for CID-103 in Immune Thrombocytopenia
BEIJING, CHINA / ACCESSWIRE / October 24, 2024 / CASI Pharmaceuticals, Inc. (NASDAQ:CASI), a biopharmaceutical company specializing in the development...